Dynavax is a biotechnology company best known for leveraging Toll-like receptor (TLR) biology to develop vaccines and immunotherapies. The organization employs roughly 275 people worldwide. Recent data shows 14 new hires and 16 departures, producing a small net decrease in overall headcount. Even with modest turnover, Dynavax maintains a multidisciplinary workforce that supports research, manufacturing, and commercial operations.
Sales & Support is Dynavax’s largest team with 108 employees, representing close to two-fifths of total staff and underscoring the company’s commercial focus on its marketed vaccines. Engineering follows with 36 employees who help scale manufacturing processes, while Business Management (29) and Finance & Administration (28) provide core corporate functions. Additional headcount is spread across Operations (16), Marketing & Product (14), and Healthcare roles (11). Smaller groups such as Education and Banking & Wealth Management currently show no dedicated staff, and 33 employees are categorized under Other, reflecting a variety of specialized positions.
Dynavax’s workforce is geographically diverse. Approximately 63 % of employees (173) work remotely or in locations classified as Other, indicating a flexible or distributed staffing model. The largest single office presence is in San Francisco with 59 employees, aligning with the company’s Bay Area headquarters and proximity to the biotech talent pool. Smaller clusters are located in the Washington, DC–Baltimore area (9), New York (8), Tampa (6), Boston (5), Minneapolis (4), Charlotte (4), and Detroit (3), illustrating Dynavax’s nationwide footprint that supports research, regulatory, and commercial activities across multiple regions.